AU2020327537A1 - New treatments involving miRNA-193a - Google Patents

New treatments involving miRNA-193a Download PDF

Info

Publication number
AU2020327537A1
AU2020327537A1 AU2020327537A AU2020327537A AU2020327537A1 AU 2020327537 A1 AU2020327537 A1 AU 2020327537A1 AU 2020327537 A AU2020327537 A AU 2020327537A AU 2020327537 A AU2020327537 A AU 2020327537A AU 2020327537 A1 AU2020327537 A1 AU 2020327537A1
Authority
AU
Australia
Prior art keywords
mirna
cancer
use according
pten
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020327537A
Other languages
English (en)
Inventor
Mir Farshid ALEMDEHY
Matheus Maria DE GUNST
Michel JANICOT
Roeland Quirinus Jozef Schaapveld
Bryony Jane TELFORD
Marion Tina Jolien VAN DEN BOSCH
Laurens Adrianus Hendricus Van Pinxteren
Sanaz YAHYANEJAD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interna Technologies BV
Original Assignee
Interna Technologies BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interna Technologies BV filed Critical Interna Technologies BV
Publication of AU2020327537A1 publication Critical patent/AU2020327537A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2020327537A 2019-08-12 2020-03-06 New treatments involving miRNA-193a Abandoned AU2020327537A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19191222 2019-08-12
EP19191222.9 2019-08-12
EP20160235.6 2020-02-28
EP20160235 2020-02-28
PCT/EP2020/055965 WO2021028081A1 (en) 2019-08-12 2020-03-06 New treatments involving mirna-193a

Publications (1)

Publication Number Publication Date
AU2020327537A1 true AU2020327537A1 (en) 2022-03-03

Family

ID=69701219

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020327537A Abandoned AU2020327537A1 (en) 2019-08-12 2020-03-06 New treatments involving miRNA-193a

Country Status (7)

Country Link
US (1) US20220275368A1 (https=)
EP (1) EP4013869A1 (https=)
JP (1) JP2022543555A (https=)
CN (1) CN114729358A (https=)
AU (1) AU2020327537A1 (https=)
CA (1) CA3148713A1 (https=)
WO (1) WO2021028081A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976058A4 (en) * 2019-06-03 2023-07-19 Carmel-Haifa University Economic Corporation Ltd. TREATMENT OF HEAD AND NECK CANCER IN HUMAN
AU2020327537A1 (en) * 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
CN114672558B (zh) * 2021-12-29 2023-08-04 河北医科大学第三医院 肝癌药物仑伐替尼耐药机制的研究方法
CN118678969A (zh) * 2022-02-22 2024-09-20 株式会社食物流变功能研究所 抗癌剂及抗癌剂的筛选方法
US20250333732A1 (en) * 2022-05-23 2025-10-30 Empirico Inc. Treatment of sos2 related diseases and disorders
CN116850289B (zh) * 2022-07-29 2025-10-28 东北大学 Plk4靶向药物在治疗对铂类药物耐药型肿瘤中的应用
CN117144008B (zh) * 2023-08-31 2024-03-08 武汉科技大学 三阴性乳腺癌生物标志物及其应用
WO2025111565A1 (en) * 2023-11-22 2025-05-30 Empirico Inc. Treatment of sos2 related diseases and disorders
WO2025155574A1 (en) * 2024-01-16 2025-07-24 University Of Houston System, Board Of Regents Modulation of akap12 signalosome
CN118671343B (zh) * 2024-06-25 2025-04-29 南昌大学第一附属医院 一种头颈鳞状细胞癌分子标记物及其应用
WO2026013165A1 (en) * 2024-07-10 2026-01-15 Université Libre de Bruxelles Combination of ship2 inhibitor and plk1 inhibitor for use in the treatment of cancer
CN118987030B (zh) * 2024-07-16 2025-05-30 广东医科大学附属医院 干预嗜碱性粒细胞exosc3在制备预防或治疗狼疮性肾炎药物中的应用
CN119015428B (zh) * 2024-10-29 2024-12-20 中国人民解放军总医院第三医学中心 一种敲低tmem91诱导肾癌细胞死亡和肿瘤免疫治疗肾癌的应用
CN120989248B (zh) * 2025-10-23 2025-12-23 山东第二医科大学 一种检测lncRNA标志物表达量的试剂在制备口腔鳞状细胞癌诊断产品或预后判断产品中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000388A2 (en) 1998-05-15 2000-01-06 Tcs Engineering Services, Inc. Enhanced aircraft cockpit configuration
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
FR2872704B1 (fr) 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AU2007254853B2 (en) 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
WO2008010558A1 (en) 2006-07-20 2008-01-24 Panasonic Corporation Ultrasonic probe
WO2009091982A1 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Mir-122 agonist
TW200948380A (en) 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
EP2591106A1 (en) * 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
EP3369818B1 (en) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna for treating head and neck cancer
US20160193252A1 (en) * 2013-08-14 2016-07-07 Reneuron Limited STEM CELL MICROPARTICLES AND miRNA
US11446398B2 (en) * 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
JP2021513508A (ja) * 2018-02-12 2021-05-27 インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． 抗がんマイクロｒｎａ及びその脂質製剤
AU2020327537A1 (en) * 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
CN115461461A (zh) * 2020-02-28 2022-12-09 因特尔纳技术有限公司 用于促进免疫原性细胞死亡的miRNA-193a

Also Published As

Publication number Publication date
WO2021028081A1 (en) 2021-02-18
CA3148713A1 (en) 2021-02-18
EP4013869A1 (en) 2022-06-22
US20220275368A1 (en) 2022-09-01
CN114729358A (zh) 2022-07-08
JP2022543555A (ja) 2022-10-13

Similar Documents

Publication Publication Date Title
EP4013869A1 (en) New treatments involving mirna-193a
Kalimutho et al. CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer
US10821142B2 (en) Cancer treatment and diagnosis
Zarredar et al. Critical microRNAs in lung cancer: recent advances and potential applications
US10876115B2 (en) Method for assaying MicroRNA, cancer therapeutic agent, and medical composition containing same for cancer therapy
WO2019083971A1 (en) METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY
US20240009223A1 (en) 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in various models of therapy-resistant cancer cells
EP3775288B1 (en) Mirnas for treatment and in vitro diagnosis of drug resistant tumors
Hengjie et al. HDAC3-mediated lncRNA-LOC101928316 contributes to cisplatin resistance in gastric cancer via activating the PI3K-Akt-mTOR pathway.
US20230136088A1 (en) miRNA-193a for Promoting Immunogenic Cell Death
Sweet-Cordero et al. The CLCF1-CNTFR axis drives an immunosuppressive tumor microenvironment and blockade enhances the effects of established cancer therapies
US20250197864A1 (en) Lncrna transcripts in melanomagenesis
US11642362B2 (en) Methods of inhibiting cell proliferation and METTL8 activity
CN105617401B (zh) miRNA的肿瘤辐射增敏及减弱辐射旁效应作用、实施方法及用途
US12173039B1 (en) TPL2 inhibiting agents, uses thereof, and detection of TPL2
Zhao et al. Dysregulation of B7 family
Buzzetti Mechanisms of medulloblastoma vulnerability and new targeted therapies
CA3025522C (en) 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in various models of therapy-resistant cancer cells
Leonardi Study of molecular pathways modulating autophagy in lung tumor cells and their impact on NSCLC tumor progression
WO2024086562A2 (en) Methods for treating or preventing neuroendocrine tumor formation using xpo1 inhibitors
WO2026024807A1 (en) Methods of treating, ameliorating or preventing cancer
Arabkari Regulation of cell fate by microRNAs during unfolded protein response and its role in cancer
Fanciullo et al. miR-126 Orchestrates an Oncogenic Program in B-Cell Precursor Acute Lymphoblastic Leukemia

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application